-transparent.png){kind=logo}
The new S3 guideline on prostate cancer includes imaging modalities applied for early detection, primary diagnosis, and staging of prostate cancer. Detection and primary diagnosis are based on digital rectal examination, serum PSA levels, and prostate biopsy. Among the imaging modalities, MRI shows the highest test quality parameters. Although MRI cannot replace biopsy to prove prostate cancer, its high negative predictive value can help to reduce the number of subsequent biopsies after negative prostate biopsy. For T-staging, MRI also demonstrates the highest test quality parameters. Its clinical application is limited, since therapeutic consequences are restricted. Due to its high specificity, MRI can save unnecessary pelvic lymph node dissections in patients at high risk for lymph node metastasis (N-staging). Risk-adjusted bone scans, complemented by additional radiological examinations if necessary, remain the standard to assess hematogenous metastasis (M staging).
U G Mueller-Lisse, and
K Miller
July 2019,
Seminars in nuclear medicine,
U G Mueller-Lisse, and
K Miller
July 2009,
Expert review of anticancer therapy,
U G Mueller-Lisse, and
K Miller
January 2009,
Advances in urology,
U G Mueller-Lisse, and
K Miller
August 1991,
The Urologic clinics of North America,
U G Mueller-Lisse, and
K Miller
March 2020,
European urology focus,
U G Mueller-Lisse, and
K Miller
April 2016,
Surgical oncology clinics of North America,
U G Mueller-Lisse, and
K Miller
January 2010,
Acta clinica Belgica,
U G Mueller-Lisse, and
K Miller
August 2013,
Clinical oncology (Royal College of Radiologists (Great Britain)),
U G Mueller-Lisse, and
K Miller
April 1991,
Seminars in oncology,
U G Mueller-Lisse, and
K Miller
January 2013,
Digestive surgery,
